
    
      25 adult subjects with moderate to severe plaque psoriasis will receive Ilumya 100mg
      subcutaneously at weeks 0, 4 and 16.

      At week 16, patients with remaining BSA ˃3% will be given HALOG ointment 0.1% to apply BID
      for 4 weeks. Patients who have ≤3% BSA at week 16 will remain on Ilumya monotherapy.

      Patients will continue to be evaluated at weeks 20 and 24.
    
  